The study revealed that the absence of interleukin (IL)-1β in JAK2-mutant HSCs led to reduced engraftment, constrained clonal expansion, a decrease in the total number of functional HSCs, and a lower rate of progression to MPN [27]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.